Polaryx Therapeutics Inc. Company Profile
NASDAQ: PLYXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 9, 11:42 AM ET
Polaryx Therapeutics at a glance
Polaryx Therapeutics Inc. (NASDAQ: PLYX) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Paramus, NJ. Polaryx Therapeutics is led by Mr. Alex Yang J.D., L.L.M. and employs about 2 people. At a market capitalization of $99.7 million, it is considered a small-cap company.
Its SEC Central Index Key (CIK) is 0002075320, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Polaryx Therapeutics do?
Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate. The company was founded in 2014 and is based in Paramus, New Jersey.
Business description based on the company's public filings.
Company information
- Legal name
- Polaryx Therapeutics Inc.
- Ticker
- NASDAQ: PLYX
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Alex Yang J.D., L.L.M.
- Employees
- 2
- Headquarters
- South Tower, Paramus, NJ, United States
- Phone
- 201 940 7236
- Website
- polaryx.com
- Market cap
- $99.69M
- SEC CIK
- 0002075320
Companies similar to Polaryx Therapeutics
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| BMEABiomea Fusion Inc. | 1.41 | +2.93% | $101.95M | vs PLYX |
| ANIXAnixa Biosciences Inc. | 2.94 | +0.86% | $102.03M | vs PLYX |
| KZIAKazia Therapeutics Limited ADR | 8.95 | +1.47% | $102.27M | vs PLYX |
| AARDAardvark Therapeutics Inc. | 4.71 | 0.00% | $103.08M | vs PLYX |
| OKUROnKure Therapeutics Inc. Class A | 2.37 | +3.04% | $95.98M | vs PLYX |
| CRBPCorbus Pharmaceuticals Holdings Inc. | 5.36 | +1.61% | $103.57M | vs PLYX |
| MISTMilestone Pharmaceuticals Inc. | 0.7567 | +6.26% | $94.21M | vs PLYX |
| CPIXCumberland Pharmaceuticals Inc. | 7.04 | +0.86% | $105.48M | vs PLYX |